Literature DB >> 19755856

Exploiting synthetic lethal interactions for targeted cancer therapy.

H Christian Reinhardt1, Hai Jiang, Michael T Hemann, Michael B Yaffe.   

Abstract

Emerging data suggests that synthetic lethal interactions between mutated oncogenes/tumor suppressor genes and molecules involved in DNA damage signaling and repair can be therapeutically exploited to preferentially kill tumor cells. In this review, we discuss the concept of synthetic lethality, and describe several recent examples in which this concept was successfully implemented to target tumor cells in culture, in mouse models, and in human cancer patients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19755856      PMCID： PMC3057180          DOI： 10.4161/cc.8.19.9626

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


  93 in total

Review 1.  The many substrates and functions of ATM.

Authors:  M B Kastan; D S Lim
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

Review 2.  Principles for the buffering of genetic variation.

Authors:  J L Hartman; B Garvik; L Hartwell
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

Review 3.  Cell cycle checkpoint signaling through the ATM and ATR kinases.

Authors:  R T Abraham
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

4.  Mutation load, functional overlap, and synthetic lethality in the evolution and treatment of cancer.

Authors:  Alexander Kamb
Journal:  J Theor Biol       Date:  2003-07-21       Impact factor: 2.691

Review 5.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair.

Authors:  Laura Spagnolo; Angel Rivera-Calzada; Laurence H Pearl; Oscar Llorca
Journal:  Mol Cell       Date:  2006-05-19       Impact factor: 17.970

7.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Authors:  Y Xu; T Ashley; E E Brainerd; R T Bronson; M S Meyn; D Baltimore
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

Review 8.  Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis.

Authors:  A M R Taylor; A Groom; P J Byrd
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

9.  Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

Authors:  Z Q Wang; B Auer; L Stingl; H Berghammer; D Haidacher; M Schweiger; E F Wagner
Journal:  Genes Dev       Date:  1995-03-01       Impact factor: 11.361

10.  Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM(-/-) and c-Abl(-/-) cells.

Authors:  Shyng-Shiou F Yuan; Hsueh-Ling Chang; Eva Y-H P Lee
Journal:  Mutat Res       Date:  2003-04-09       Impact factor: 2.433
View more
  48 in total

Review 1.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

2.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Authors:  Amy Baldwin; Dorre A Grueneberg; Karin Hellner; Jacqueline Sawyer; Miranda Grace; Wenliang Li; Ed Harlow; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

3.  Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients.

Authors:  Veronika Navrkalova; Leona Raskova Kafkova; Vladimir Divoky; Sarka Pospisilova
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

Review 4.  The changing landscape of phase I trials in oncology.

Authors:  Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2015-11-10       Impact factor: 66.675

Review 5.  DNA double-strand break repair pathway choice - from basic biology to clinical exploitation.

Authors:  Ron D Jachimowicz; Jonas Goergens; H Christian Reinhardt
Journal:  Cell Cycle       Date:  2019-05-22       Impact factor: 4.534

6.  MicroRNA-based screens for synthetic lethal interactions with c-Myc.

Authors:  Youjun Li; Yahui Zhu; Edward V Prochownik
Journal:  RNA Dis       Date:  2016-05-30

Review 7.  Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after.

Authors:  Jason M Beckta; Syed Farhan Ahmad; Hu Yang; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

8.  Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin.

Authors:  Darin Salloum; Suman Mukhopadhyay; Kaity Tung; Aleksandra Polonetskaya; David A Foster
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

9.  Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.

Authors:  Onica Le Gendre; Ayisha Sookdeo; Stephie-Anne Duliepre; Matthew Utter; Maria Frias; David A Foster
Journal:  Mol Cancer Res       Date:  2013-02-26       Impact factor: 5.852

10.  A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo.

Authors:  Sandra Morandell; H Christian Reinhardt; Ian G Cannell; Jacob S Kim; Daniela M Ruf; Tanya Mitra; Anthony D Couvillon; Tyler Jacks; Michael B Yaffe
Journal:  Cell Rep       Date:  2013-11-14       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.